ALEXANDRA HOSPITAL

Cabazitaxel Shows Efficacy in Metastatic Castration-Resistant Prostate Cancer with Osseous Metastases

6 months ago

• A Phase II study (CabaBone) confirms cabazitaxel's efficacy in metastatic castration-resistant prostate cancer (mCRPC) patients, including those with HRR mutations, previously treated with docetaxel. • The study found a 6-month progression-free survival rate of 47% and a 12-month overall survival rate of 70% in mCRPC patients with bone metastases treated with cabazitaxel. • Reactive hematopoiesis in bone marrow biopsies was associated with improved survival, suggesting bone biomarkers could predict cabazitaxel efficacy in mCRPC patients. • No new safety issues were detected, reinforcing cabazitaxel as a viable treatment option for mCRPC patients with osseous metastases.